drugset / Trial / NCT00151528

An Open-Label Trial of Pregabalin in Patients With Fibromyalgia

NCT00151528

Phase 3 Completed 428 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The main purpose of this protocol is to evaluate the long-term safety of pregabalin in patients who participated in the previous fibromyalgia Study A0081056 and who wish to receive open-label pregabalin therapy.

Timeline

Start
2005-01
Primary completion
Completion
2006-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Pregabalin Small molecule 75 mg
Subject Pregabalin Small molecule 300 mg

Indications